
Abstract Background Post‐streptococcal glomerulonephritis (PSGN) is an immune‐mediated sequela of group A streptococcal (GAS) infections, with nephritogenic GAS antigens implicated in its pathogenesis. Seroepidemiological evidence also implicates GAS streptococcal inhibitor of complement (SIC) in the development of PSGN. This association is supported by elevated anti‐SIC antibody responses in patients with PSGN, suggesting a possible role for these antibodies in disease pathogenesis. Methods To investigate whether antibodies generated against SIC are associated with renal pathology, Lewis rats were administered recombinant SIC (rSIC), its domain containing the long repeat region (LRR) and proline‐rich region (PRR), or rSIC combined with inactivated whole‐cell GAS (IWG) in a series of experiments. Serum antibody responses were evaluated using enzyme‐linked immunosorbent assays. Renal alterations were assessed by biochemical analyses of serum and urinary albumin, creatinine, and urea; urinalysis for microhematuria and albumin‐to‐creatinine ratio; histopathology; and immunofluorescence analysis of immunoglobulin G (IgG) and complement C3 deposition. Systemic complement activation was evaluated by measuring serum C3a levels. Results Although robust anti‐SIC antibody responses ( p < 0.0001) were observed in all rats exposed to the various SIC formulations or domain, no renal functional impairment, histopathological injury, urinary abnormalities, or significant alterations in serum C3a levels were identified. In the absence of overt renal abnormalities, immunofluorescence revealed only focal low‐grade glomerular IgG deposition but no detectable C3 deposition. Conclusions In this Lewis rat model, antibodies to rSIC did not drive PSGN‐like renal pathology. This suggests that SIC‐specific humoral responses alone may be insufficient for disease development, potentially reflecting the multifactorial nature of PSGN pathogenesis.
Abstract Background Venopulmonary extracorporeal membrane oxygenation (VP ECMO) using a right atrium‐to‐pulmonary artery configuration has emerged as an attractive strategy for right ventricular failure, bridge‐to‐lung transplantation, and selected cases of severe respiratory failure. Despite increasing clinical use of dual‐lumen cannulas, dedicated large‐animal models remain poorly described. We developed a reproducible swine model of VP ECMO using a dual‐lumen right atrium‐to‐pulmonary artery cannula. Methods Twelve adult male Landrace pigs underwent attempted bedside cannulation through the right internal jugular vein. After ultrasound‐guided vascular access, a pigtail catheter was advanced into the pulmonary artery under fluoroscopic guidance and exchanged for an ultra‐stiff guidewire. A 29‐Fr dual‐lumen cannula was then positioned between the right atrium and pulmonary artery and connected to a centrifugal pump and membrane oxygenator. Animals were maintained on VP ECMO support for 12 h. Results Successful VP ECMO implantation was achieved in 8 of 12 animals (67%). Median maximal blood flow was 3.7 L/min (3.5–4.0). Median drainage and return pressures were −80 mmHg (−70 to −100) and 110 mmHg (100–122), respectively. Median pre‐oxygenator venous oxygen saturation was 67% (65–75). Baseline pulmonary artery pressure was normal (20 mmHg [15–25]). Four procedures were unsuccessful, including three episodes of ventricular fibrillation and one cardiac tamponade. After refinement of the implantation technique, no clinically significant cannula migration or flow deterioration was observed during the 12‐h observation period. Conclusions This study establishes a reproducible large‐animal model of dual‐lumen VP ECMO suitable for procedural training, translational research, and future investigations.
Abstract Background The most frequent underlying cause of death for type 1 diabetes mellitus (T1DM) is cardiovascular damage. Extreme fat consumption causes deterioration in lipid metabolism in DM; however, how a high‐fat diet (HFD) affects the progression of pathological process of diabetic myocardial dysfunction, especially the identification of candidate intervention targets, has become an urgent need. Methods The T1DM Syrian golden hamster model was induced by streptozotocin (STZ) injection, and a 6‐week HFD intervention (42.0% calories from fat) was given in the early stage of T1DM. Changes in body weight and biochemical indicators of glucose and lipid were tracked weekly. Echocardiography and histopathology were used to evaluate how HFD affected myocardial remodeling at the overall, ultramicroscopic, and microscopic levels. Using proteomics, the STRING database, molecular biology analysis, and reverse validation via an in vitro model, we further gathered mechanistic insights. Results HFD caused severe lipid metabolism disorders in the STZ/HFD group. HFD induced more severe inhomogeneous hypertrophy, cardiac diastolic dysfunction, interstitial collagen deposition, and lipid droplet accumulation in the myocardium of T1DM hamsters. Mechanistically, HFD influenced the protein composition profile, mainly in lipid metabolism as well as mitochondrial metabolism. Furthermore, HFD caused more severe damage to mitochondrial morphology. Moreover, metabolic disorder of branched‐chain amino acids (BCAAs) was mediated by PPM1K, which finally aggravated surplus oxidative stress accumulation and damage in the myocardium of T1DM hamsters. Conclusions Mitochondrial repair, especially the metabolic replenishment of BCAAs, holds potential as a treatment in situations with excessive fat intake in T1DM and should be investigated in vivo and in clinical validation studies in the future.
Abstract Background Research on articular cartilage development provides a foundation for the repair and regeneration of cartilage following injury. Methods In this study, eight embryonic time points were selected: embryonic days 30 (E30), E35, E45, E55, E75, E85, E90, and E100, along with knee joints from newborn (P0) and 30 day old (P30) piglets. The dynamic developmental characteristics of knee cartilage were systematically analyzed by Safranin O‐Fast Green, Toluidine blue, and Masson staining. Results The results indicate that the mesenchymal condensation (interzone) of the knee joint has formed by embryonic day 30 (E30), marking the initiation of joint development. Chondrification commences in the diaphyses of the femur and tibia, establishing the foundation for primary ossification in femur and tibia regions at E35. By E45, the epiphyseal cartilage cells have distinctly differentiated into two morphologically distinct populations, round epiphyseal chondrocytes and spindle‐shaped growth plate chondrocytes. At E55, cartilage canals begin to emerge in the cartilage zone. The number of cartilage canal and chondrocytes progressively increase from E75 to E90. Growth plate chondrocytes progressively differentiate from a disorganized, undifferentiated state into a highly organized, spindle‐shaped, columnar array. The secondary ossification center of the knee joint appears at E100, concomitant with hypertrophy of adjacent chondrocytes and resorption of cartilage canals. From postnatal day 0 (P0) to P30, the secondary ossification center undergoes progressive peripherally expansion. By P30, partial chondrocytes display reduced Safranin O staining intensity, indicative of diminished extracellular matrix secretion. By P30, secondary ossification has progressed sufficiently to replace the cartilaginous zone proximal to the growth plate with mineralized tissue. The growth plate becomes completely separated from the epiphyseal cartilage zone, marking the completion development of growth plate. Conclusions This study dynamically charts the developmental process of the knee joint cartilage from the embryonic stage to postnatal life, revealing key developmental events including the origin of knee joint development, chondrification, primary ossification, secondary ossification, formation of the cartilage canals and growth plate. The results provide foundational material for research in cartilage tissue engineering and regenerative medicine.
Abstract Post‐stroke cognitive impairment (PSCI) is a major cause of long‐term disability after ischemic stroke, yet its mechanisms remain incompletely explained by infarct volume, lesion location, or conventional vascular risk factors alone. Animal models are indispensable for clarifying how ischemic injury evolves into delayed cognitive dysfunction and for determining which mechanisms are experimentally tractable, reproducible, and translationally relevant. This review examines PSCI from a neurovascular trafficking perspective, focusing on how laboratory animal models can be used to investigate secretory pathway stress, endolysosomal dysfunction, autophagy‐lysosomal flux, extracellular vesicle signaling, blood–brain barrier disruption, glial reactivity, myelin debris clearance, white matter injury, and cognition‐relevant behavioral phenotypes. Rodent models of transient or permanent middle cerebral artery occlusion, photothrombotic stroke, embolic stroke, chronic cerebral hypoperfusion, bilateral carotid artery stenosis, and subcortical white‐matter injury each reproduce selected components of the human PSCI spectrum. No single model fully captures the temporal, vascular, cellular, and cognitive complexity of human PSCI; therefore, model selection should be driven by the mechanistic question, disease phase, vascular pathology, cellular compartment, cognitive domain, and welfare burden under investigation. The central argument is not that neurovascular trafficking failure is already a proven causal pathway, but that well‐designed animal studies can test, refine, or falsify this hypothesis. Future studies should integrate model validity, translational rigor, and welfare refinement through longitudinal cognitive testing, multimodal imaging, cell‐specific molecular profiling, extracellular vesicle phenotyping, intervention‐based validation, randomization, blinding, sample‐size justification, humane endpoints, perioperative care, and transparent reporting.